Evidence map›Paper›PMID 36717968›Full record

ArticleBritish journal of haematology2023

Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?

Oriol Calvete, Julia Mestre, Arda Durmaz, Carmelo Gurnari, Jaroslaw P Maciejewski, Francesc Solé

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oriol CalveteMyelodysplastic Syndrome Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0002-2623-2876
Julia MestreMyelodysplastic Syndrome Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arda DurmazDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Ohio, Cleveland, USA.
Carmelo GurnariDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Ohio, Cleveland, USA.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Ohio, Cleveland, USA.
Francesc SoléMyelodysplastic Syndrome Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.

Funding

Therapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7M
NHLBI NIH HHS R35 HL135795
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myelodysplastic SyndromesDisease SusceptibilityGenetic Predisposition to DiseaseGerm-Line MutationHumansMutationcurrent guidelinesgenetic predispositiongermline variantsmyelodysplastic syndrome (MDS)Variant allele frequency (VAF)

Identifiers

PMID36717968
PMCPMC11104019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.